News Network

Join us LIVE at this year's 2023 ESMO Congress! OncLive® will broadcast a series of interviews with top thought leaders in breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, and gynecologic malignancies. The experts will share their insights and reactions to the pivotal data presented during the conference.

Expert perspectives on the current diagnostic and treatment landscape for patients with low-grade serous ovarian cancer and how recent learnings have impacted real-world practice.

Joseph Gligorov, MD, reviews advancements in the treatment of HER2-positive breast cancer, including the pivotal DESTINY-Breast03 study, global perspectives, sequencing strategies based on French real-world evidence, and the management of adverse events in advanced therapies.

Giselle Sholler, MD, and Anurag Agrawal, MD, discuss the changing landscape of treatment strategies for patients with high-risk neuroblastoma and review key clinical trial data presented at the ASCO 2023 Annual Meeting.

Jae Park, MD, reviews key data in the management of relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) recently presented at the ASCO 2023 Annual Meeting.

Preet M. Chaudhary, MD, PhD and Noah Merin, MD, PhD discuss the chronic graft versus host disease treatment landscape, covering first- and second-line treatments and emergent trial data.

Following the 2023 ASCO Annual Meeting, Tanios S. Bekaii-Saab, MD, discusses recent data updates and provides clinical insights on the evolving treatment landscape for metastatic colorectal cancer.

Megan Kruse, MD, reviews updates from the 2023 ASCO Annual Meeting and offers insights onthe evolving treatment landscape for HER2+ metastatic breast cancer.

Updates in Philadelphia-positive acute lymphoblastic leukemia treatment are highlighted following ASCO 2023.

Brian T. Hill MD, PhD, and Paulo Ghia, MD engage with recent data focusing on BTKis in CLL presented at the ICML 2023 Annual Meeting as well as how that data may be applied to clinical practice.

Join us LIVE at this year's 2023 ASCO Annual Meeting! OncLive® will broadcast a series of interviews with top thought leaders in breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, gynecologic malignancies, melanoma, and sarcoma. The experts will share their insights and reactions to the pivotal data presented during the conference.

Tanios S. Bekaii-Saab, MD, FACP describes the current colorectal cancer (CRC) treatment landscape, shares relevant updates from the American Society for Clinical Oncology’s Gastrointestinal Cancers Symposium 2023, and discusses his hopes for the future of the field.

Expert perspectives on the emerging role of navitoclax, a novel BCL-XL inhibitor, in the treatment armamentarium for myelofibrosis and T-cell acute lymphoblastic leukemia, respectively.

Expert perspectives from Amod Sarnaik, MD, and Krishna Komanduri, MD, on the evolving role of tumor-infiltrating lymphocyte therapy in solid tumors, following the Society for Immunotherapy of Cancer (SITC) 2022 meeting.

Experts review key updates in LBCL management from the ASH 2022 annual meeting.

Loretta J. Nastoupil, MD, and Marc S. Hoffman, MD, review key updates on the role of CAR T-cell therapy in large B-cell lymphoma (LBCL), follicular lymphoma, and non-Hodgkin’s lymphoma, and discuss how the data applies to clinical practice.

Experts on myelofibrosis and myelodysplastic syndromes discuss recent data updates, including those presented at the 2022 American Society of Hematology (ASH) Annual Meeting, and provide their outlook on the future of treatment for each.

Charles E. Geyer, MD and Ian E. Krop, MD, PhD review current trends in the breast cancer treatment landscape, discuss new data presented at the 2022 San Antonio Breast Cancer Symposium as well as other major findings presented over the course of the year.

Dr. Ghassan Abou-Alfa leads a small panel including Dr. Robert Lewandowksi and Dr. Amit Singal in a multidisciplinary discussion of hepatocellular carcinoma and updates to the treatment armamentarium.

Harry Yoon, MD and Nabil Saba, MD, FACP, discuss recent data on novel regimens for first-line treatment of advanced/metastatic ESCC, including the immunotherapy regimen tislelizumab.

Hans Hammers, MD, PhD, and Moshe Ornstein, MD, MA, discuss data updates in advanced renal cell carcinoma (RCC) that were presented at the recent 2022 International Kidney Cancer Symposium.

Join us LIVE at this year's 2022 ASH Annual Meeting and Exposition! OncLive® will broadcast a series of interviews with top thought leaders in multiple myeloma, acute myeloid leukemia, non-Hodgkin lymphoma, graft-vs-host disease, chronic lymphocytic leukemia, and myeloproliferative neoplasms. The experts will share their insights and reactions to the pivotal data presented during the conference.

Dr Nikhil Khushalani reviews recent data updates for the treatment of non-melanoma skin cancers focusing on cutaneous squamous cell carcinoma and basal cell carcinoma.

Drs Jeanny B. Aragon-Ching and Srikala Sridhar review key updates in the management of urothelial carcinoma from data presented in 2022.

Expert oncologists share their perspectives on key updates in the management of hormone receptor–positive metastatic breast cancer from the past year.

Join us LIVE at this year's 2022 ESMO Congress! OncLive® will broadcast a series of interviews with top thought leaders in breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, and gynecologic malignancies. The experts will share their insights and reactions to the pivotal data presented during the conference.

Aditya Bardia, MD, MPH discusses the present and prospective clinical applications of ctDNA monitoring informed by promising data presented at the ASCO 2022 Annual Meeting.

Expert oncologists incorporate personal experience with data from the recent ASCO 2022 annual meeting to highlight optimal testing and management strategies in breast cancer.

Omid Hamid, MD, and Ryan Sullivan, MD, discuss new updates in uveal melanoma, and an exciting, recently approved agent for treatment of metastatic disease.